FindTrial
Sign In

Clinical study of tizanidine combined with pregabalin on post herpes neuralgia

Clinical study of tizanidine combined with pregabalin on post herpes neuralgia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000040108
Enrollment
Unknown
Registered
2020-11-21
Start date
2020-12-01
Completion date
Unknown
Last updated
2021-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post herpes neuralgia

Interventions

1:pregabalin
2:tizanidine+pregabalin

Sponsors

Affiliated Hospital of Qingdao University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Comply with the diagnosis of post herpes neuralgia; 2. Aged 30 to 70 years old; 3. VAS score >=4; 4. provide informed consent.

Exclusion criteria

Exclusion criteria: 1. Communication disorder; 2. Severe heart, lung, liver and kidney dysfunction; 3. Definitely diagnosed neuropsychiatric diseases, such as dementia, Parkinson's syndrome, myasthenia gravis, schizophrenia, epilepsy, etc.; 4. Patients with malignant tumors and their cachexia; 5. Have used glucocorticoids and immunosuppressants within one week before joining the group; 6. During pregnancy and lactation.

Design outcomes

Primary

MeasureTime frame
VAS;—

Secondary

MeasureTime frame
SF-12;PGIC;short-form McGill;—

Countries

China

Contacts

Public ContactMeng Chao

Affiliated Hospital of Qingdao University

mengchao1119@hotmail.com+86 18661808786

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026